1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.
2.Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015; 21:12003–21.
3.Li D, Kang J, Golas BJ, Yeung VW, Madoff DC. Minimally invasive local therapies for liver cancer. Cancer Biol Med. 2014; 11:217–36.
4.Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004; 239:150–9.
5.Ata R, Antonescu CN. Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer. Int J Mol Sci. 2017; 18.
6.Caswell PT, Vadrevu S, Norman JC. Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol. 2009; 10:843–53.
7.Flintoff-Dye NL, Welser J, Rooney J, Scowen P, Tamowski S, Hatton W et al. Role for the alpha7beta1 integrin in vascular development and integrity. Dev Dyn. 2005; 234:11–21.
8.Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN et al. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst. 2007; 99:868–80.
9.Ming XY, Fu L, Zhang LY, Qin YR, Cao TT, Chan KW et al. Integrin alpha7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma. Nat Commun. 2016; 7:13568.
10.Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME et al. Integrin alpha7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. Cell Stem Cell. 2017; 21:35–50 e9.
11.Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR, Cai JB et al. Galectin–1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death Dis. 2016; 7:e2201.
12.Su Y, Guan XQ, Liu FQ, Wang YL. The effects of MIBG on the invasive properties of HepG2 hepatocellular carcinoma cells. Int J Mol Med. 2014; 34:842–8.
13.Choi C, Kwon J, Lim S, Helfman DM. Integrin beta1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer. Oncotarget. 2016; 7:63466–87.
14.Xia H, Nho RS, Kahm J, Kleidon J, Henke CA. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem. 2004; 279:33024–34.
15.Boppart MD, Burkin DJ, Kaufman SJ. Activation of AKT signaling promotes cell growth and survival in alpha7beta1 integrin-mediated alleviation of muscular dystrophy. Biochim Biophys Acta. 2011; 1812:439–46.